To present a clinical case of a patient with BRAF V600E-mutant metastatic colorectal cancer (BRAF mCRC) who experienced a prolonged response to treatment with a combination of vemurafenib and cobimetinib.
Approach:
Patient Background: A 60-year-old male diagnosed with BRAF V600E-mutant metastatic colorectal cancer (BRAF mCRC) in 2019 underwent first-line treatment with FOLFOXIRI plus bevacizumab, followed by curative surgery after achieving a partial response.
Treatment Details: The patient was enrolled in a phase II clinical trial and received vemurafenib and cobimetinib, achieving stable disease for nearly four years.
Key Findings:
The patient maintained stable disease with manageable side effects over nearly four years.
This case represents the longest documented response to a MEKi-based regimen in BRAF mCRC.
Interpretation:
The findings suggest that MEK inhibitors may warrant reconsideration in the treatment of BRAF mCRC.
Limitations:
The case is a single patient report, limiting generalizability.
No comparative data with standard treatments were provided.
Conclusion:
The case highlights the importance of personalized genomic profiling and treatment sequencing in BRAF mCRC.
by Michela Guardascione, Monica Rizzetto, Luisa Foltran, Paola Di Nardo, Marco de Scordilli, Elena Ongaro, Arianna Fumagalli, Anna Calabrò, Andrea Botticelli, Paolo Marchetti, Fabio Puglisi
An updated clinical practice guideline from the American Society for Radiation Oncology substantially expands and modernizes recommendations for the use of radiation therapy in pancreatic cancer.
